Skip to content

The effect of oral use of Mentha Longifolia capsule on the symptoms of premenstrual and the severity and duration of menstrual pain

The effect of oral use of Mentha Longifolia capsule on the symptoms of premenstrual syndrome and primary dysmenorrhea

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210630051749N1
Enrollment
64
Registered
2021-07-05
Start date
2021-07-11
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: primary dysmenorrhea. Condition 2: Premenstrual syndrome. Primary Dysmenorrhea Pain localized to other parts of lower abdomen

Interventions

Intervention 1: Intervention group: In the intervention group, mint oral capsule will be used once a day from 7 days before the start of menstruation until the first 3 days of menstruation. Interventi

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Be Iranian and single. Be a resident of the dormitories of Mashhad University of Medical Sciences. Have regular menstruation Have premenstrual syndrome and primary dysmenorrhea at the same time. Be 18-35 years old. No medication No allergies to mint No alcohol or drugs or tobacco No diet No disease

Exclusion criteria

Exclusion criteria: Discontinuation of medication or irregular use of medication (not taking medication twice or more) Have a BMI of more than 30. Be a professional athlete. Suffer from depression, stress and anxiety . Experience an unfortunate or stressful event while studying. Has used traditional medicine methods to reduce symptoms and improve pain. Married while studying.

Design outcomes

Primary

MeasureTime frame
Mean score of total premenstrual syndrome symptoms, severity and duration of dysmenorrhea. Timepoint: Mean score of total symptoms of premenstrual syndrome, severity and duration of dysmenorrhea at the beginning of the study (before the intervention) and 1 and 2 months after the intervention. Method of measurement: The mean total score of premenstrual syndrome symptoms will be assessed by COPE premenstrual events calendar form and the severity and duration of dysmenorrhea in the first and second months of the treatment cycle, by visual pain scale and COX scale and by patients' self-report.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Ebrahimzadehzagami

Mashhad University of Medical Sciences

EbrahimzadehzagamiS@mums.ac.ir+98 51 3859 1511

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026